Elevation Oncology (ELEV)
(Delayed Data from NSDQ)
$3.53 USD
-0.15 (-4.08%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.52 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Elevation Oncology, Inc. [ELEV]
Reports for Purchase
Showing records 1 - 20 ( 53 total )
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Unveiling of a New HER3-ADC Candidate Expected in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Initial EO-3021 Data in mid 3Q:24, HER3 ADC Selection in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
HER-3 ADC Generates Promising Preclinical Data, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Programs Expanding; New PT Up To $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EO-3021 Data in Mid-2024; Encouraging Pipeline Updates
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EO-3021 Clinical Program Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Developing an ADC For a Challenging Target; Initiate With Buy and a $1.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Partner Data Bolsters Outlook for EO-3021; Increasing PT to $6 (from $4)
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Initial Look at EO-3021 Ph 1 Data at ASCO; Promising Efficacy in Gastric Cancer
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R